Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
Rhea-AI Summary
Galmed Pharmaceuticals (NASDAQ: GLMD) completed its acquisition of Colospan, gaining CG-100, a CE-marked colorectal device commercial-ready in the EU/Israel with a dedicated German OPS code.
Restructured terms replace a $2.0M share issue with an $800K extra cash payment and an up-to-$2.0M tiered earnout starting Q3 2027. CG-100 has supportive clinical data from four trials (97 patients) and may generate revenue in 2026.
AI-generated analysis. Not financial advice.
Positive
- Restructured deal removes immediate $2.0M share issuance, reducing near-term shareholder dilution
- Additional $800K cash payment supported by $15.6M cash balance as of March 31, 2026
- Earnout capped at $2.0M, single-digit percentage of net sales from Q3 2027
- Acquisition adds CE-marked, AMAR-approved CG-100 with German OPS code 5-46b.2
- Potential to begin generating top-line revenue from CG-100 in 2026
- Clinical data: 90% of CG-100 patients avoided stoma creation in four trials (97 patients)
- Lower anastomotic leak rate of 3% vs 6.3% in stoma patients reported for CG-100
- No device migration, 0% mortality vs 1.3%, and 3% Clavien-Dindo 3–5 adverse events vs 22.1% in stoma group
- None of the CG-100 patients required permanent stoma vs 23.5% in temporary stoma group
- Strategic fit with Galmed’s GI focus and Phase 3–ready Aramchol program
Negative
- Upfront cash outlay increases by $800K compared with prior share-based structure
- Future earnout liability of up to $2.0M tied to net sales from Q3 2027
- Earnout may accelerate upon strategic transaction or equity financings of at least $17.5M
News Market Reaction – GLMD
On the day this news was published, GLMD gained 1.38%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.8% during that session. Argus tracked a trough of -18.0% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $61K to the company's valuation, bringing the market cap to $4.46M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
GLMD’s peers show mixed moves, with several biotech names down and only one in the momentum scan moving up, suggesting the reaction is more stock-specific than a broad sector rotation.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Acquisition agreement | Positive | -12.4% | Signed definitive agreement to acquire Colospan and build a GI-focused platform. |
Prior acquisition news on Colospan led to a -12.36% move, hinting at investor caution around deal-related headlines.
Historical Comparison
In the past 6 months, GLMD’s only prior acquisition headline, also about Colospan, saw a -12.36% move, suggesting investors have been skeptical toward deal-driven expansion.
Acquisition news has progressed from signing the Colospan share purchase agreement to today’s closing and restructured, more earnout-heavy consideration terms.
Regulatory & Risk Context
Reported short interest appears relatively low, pointing to limited short-squeeze risk and typically modest volatility from forced covering alone.
Market Pulse Summary
This announcement confirms closing of the Colospan deal on more earnout-based terms and highlights strong CG-100 data in 97 patients. With cash of $15.6M and low short interest, future equity raises and commercialization execution remain key watchpoints.
Key Terms
ce marked regulatory
clavien-dindo medical
pivotal study medical
AI-generated analysis. Not financial advice.
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ: GLMD) with a commercially ready product in the EU/
Strategic and Financial Highlights
Restructured Anti-Dilutive Financial Terms: To diminish the dilutive event on GLMD's existing shareholders, Galmed and Colospan agreed that in lieu of issuing
- Galmed is laying the groundwork for a pan-European launch of CG-100, a less invasive intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas.
- CG-100 benefits from strong safety and efficacy clinical data based on 4 clinical trials conducted in
Europe between 2014 and 2024. - In addition to generating top-line revenue already in 2026, "real-life" data from patients using CG-100 is planned to be submitted to the FDA to support Colospan' s Pivotal study
- Strategic Synergy: Establishing a unified GI platform by leveraging drug development expertise with medical device commercialization.
RAMAT GAN,
As a result of the acquisition, Colospan became a wholly owned subsidiary of Galmed. The acquisition of Colospan gives Galmed a commercial-ready product in the EU/
To date, 97 patients have been treated with the CG-100 worldwide across four clinical trials in
Strategic Synergy
"By combining resources, Galmed plans to deliver a clinically compelling and economically meaningful tool to reshape the standard of care for colorectal resection patients worldwide," said Allen Baharaff, Co-founder and Chief Executive Officer of Galmed. "The acquisition of Colospan aligns with our long-term strategic focus which remains the GI space. We strongly believe that CG-100 together with the advancement of our Ph 3 ready lead drug candidate, Aramchol, for GI related oncology indications will establish Galmed as a specialty GI medtech and biopharmaceutical platform."
Mr. Baharaff continued: "While the original terms of the acquisition contained an immediate dilutive payment in ordinary shares of
ABOUT GALMED PHARMACEUTICALS LTD.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is an
ABOUT COLOSPAN LTD.
Colospan Ltd. is a commercial-stage medical device company headquartered in Kfar Saba, Israel. Its flagship product, CG-100, is an intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to standard surgical practice. CG-100 was granted FDA Breakthrough Device Designation, is CE marked under the EU Medical Device Regulation, and is approved for investigational use in the United States under an FDA approved IDE. The device is not approved for commercial use in the US. For more information, visit www.colospan.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated or expected events, activities, trends, or results as of the date they are made, including statements regarding the expected benefits of the acquisition. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
Factors that could cause differences include, but are not limited to Galmed's inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future performance and growth of Colospan; Galmed and Colospan's ability to execute their business plans and strategy and to receive regulatory approvals; potential litigation involving the parties; changes in domestic and foreign business, market, financial, political and legal conditions; market adoption and pricing barriers; intellectual property enforcement or infringement claims; manufacturing and supply chain constraints; intense industry competition; the ability to maintain listing on the Nasdaq Capital Market; geopolitical events, including the security situation in Israel; regulatory changes; access to additional financing; and other risks and uncertainties indicated from time to time in filings with the SEC by Galmed Additional risks relating to Colospan's product and its strategy are detailed in a report on Form 6-K filed by Galmed with the SEC on June 8, 2026 and risks associated with Galmed are detailed in Galmed's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 under the heading "Risk Factors." Galmed undertakes no obligation to publicly update or revise any forward-looking statements to reflect new information, change in expectations, subsequent events, or otherwise, except as required by law.
Logo: https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg
View original content:SOURCE Galmed Pharmaceuticals Ltd.